[HTML] springer.com

[HTML][HTML] Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo, K Itoh… - Clinical and …, 2022 - Springer
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …
被引用次数：15 相关文章

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.

M Toda, K Fujii, A Yoshifuji, Y Kondo… - Clinical & …, 2022 - search.ebscohost.com
Background: Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo… - Clinical and …, 2022 - keio.elsevierpure.com
Background: Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo, K Itoh… - Clinical and …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Critical coronavirus disease 2019 (COVID-19) has a high fatality rate, especially in …
[PDF] d-nb.info

[PDF][PDF] Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID‑19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo, K Itoh, K Sekine… - 2021 - d-nb.info
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

T Masataro, F Kentaro, Y Ayumi… - Clinical and …, 2022 - search.proquest.com
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.

M Toda, K Fujii, A Yoshifuji, Y Kondo, K Itoh… - Clinical and …, 2021 - europepmc.org
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo… - Clinical and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …
[HTML] nih.gov

[HTML][HTML] Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo… - Clinical and …, 2022 - ncbi.nlm.nih.gov
Background Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …

Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients

M Toda, K Fujii, A Yoshifuji, Y Kondo… - Clinical and …, 2022 - keio.elsevierpure.com
Background: Critical coronavirus disease 2019 (COVID-19) has a high fatality rate,
especially in hemodialysis (HD) patients, with this poor prognosis being caused by systemic …